Yevgeny Valenrod

Array ( [id] => 16204726 [patent_doc_number] => 20200237716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => ALDA-1 TREATMENT AND PREVENTION OF PULMONARY DISEASE [patent_app_type] => utility [patent_app_number] => 16/839517 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9340 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16627409 [patent_doc_number] => 20210046062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => 1,4-DIHYDROPYRIDINE COMPOSITIONS, METHODS OF MAKING AND USE [patent_app_type] => utility [patent_app_number] => 16/815776 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13401 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16815776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18543701 [patent_doc_number] => 11717027 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Smoking device [patent_app_type] => utility [patent_app_number] => 16/801898 [patent_app_country] => US [patent_app_date] => 2020-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 45 [patent_no_of_words] => 28576 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16801898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16072043 [patent_doc_number] => 20200190008 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS [patent_app_type] => utility [patent_app_number] => 16/799176 [patent_app_country] => US [patent_app_date] => 2020-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16799176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16296342 [patent_doc_number] => 20200282065 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => STABILIZING EXCIPIENTS FOR THERAPEUTIC PROTEIN FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/789628 [patent_app_country] => US [patent_app_date] => 2020-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14936 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16789628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282595 [patent_doc_number] => 20200276197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => (4-((3R,4R)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6-(((2R,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4-YL)METHANONE CITRATE [patent_app_type] => utility [patent_app_number] => 16/787433 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282595 [patent_doc_number] => 20200276197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => (4-((3R,4R)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6-(((2R,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4-YL)METHANONE CITRATE [patent_app_type] => utility [patent_app_number] => 16/787433 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19839022 [patent_doc_number] => 12251376 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Combinations with thiazolidinediones for use in the prevention or treatment of abnormal bone growth [patent_app_type] => utility [patent_app_number] => 17/429902 [patent_app_country] => US [patent_app_date] => 2020-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 7 [patent_no_of_words] => 5947 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16204706 [patent_doc_number] => 20200237696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS [patent_app_type] => utility [patent_app_number] => 16/781971 [patent_app_country] => US [patent_app_date] => 2020-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15365 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16781971 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655328 [patent_doc_number] => 20220175793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => THE USE OF AN MGLUR5 ANTAGONIST FOR TREATING OPIOID ANALGESIC TOLERANCE [patent_app_type] => utility [patent_app_number] => 17/310287 [patent_app_country] => US [patent_app_date] => 2020-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17310287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503372 [patent_doc_number] => 20220096474 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION [patent_app_type] => utility [patent_app_number] => 17/425576 [patent_app_country] => US [patent_app_date] => 2020-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16304094 [patent_doc_number] => 10772865 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-15 [patent_title] => Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy [patent_app_type] => utility [patent_app_number] => 16/744433 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7036 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16744433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19809442 [patent_doc_number] => 12240812 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof [patent_app_type] => utility [patent_app_number] => 17/423248 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 18305 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 842 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17423248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480486 [patent_doc_number] => 20220087990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => APPLICATION OF RIFAMYCIN-QUINOLIZIDONE CONJUGATE MOLECULE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF [patent_app_type] => utility [patent_app_number] => 17/421388 [patent_app_country] => US [patent_app_date] => 2020-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5735 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17421388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480486 [patent_doc_number] => 20220087990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => APPLICATION OF RIFAMYCIN-QUINOLIZIDONE CONJUGATE MOLECULE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF [patent_app_type] => utility [patent_app_number] => 17/421388 [patent_app_country] => US [patent_app_date] => 2020-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5735 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17421388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19700042 [patent_doc_number] => 12194040 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => FAK inhibitor and drug combination thereof [patent_app_type] => utility [patent_app_number] => 17/418678 [patent_app_country] => US [patent_app_date] => 2019-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 8617 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17418678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15797049 [patent_doc_number] => 20200121667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => Inhibitors Of The Interaction Between MDM2 And P53 [patent_app_type] => utility [patent_app_number] => 16/718955 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16718955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18101169 [patent_doc_number] => 11541037 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Alkaloids from sponge, scaffolds for the inhibition of human immunodeficiency virus (HIV) [patent_app_type] => utility [patent_app_number] => 16/713607 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 8620 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16713607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16009071 [patent_doc_number] => 20200179378 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => Compositions, Devices, and Methods for Treating or Preventing Headaches [patent_app_type] => utility [patent_app_number] => 16/710538 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35205 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 195 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16710538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16450922 [patent_doc_number] => 20200360348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/710688 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16710688 [rel_patent_id] =>[rel_patent_doc_number] =>)